Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (EP0833659) THERAPEUTIC FRAGMENTS OF VON WILLEBRAND FACTOR

Office : European Patent Office
Application Number: 96918137 Application Date: 06.06.1996
Publication Number: 0833659 Publication Date: 08.04.1998
Publication Kind : B1
Prior PCT appl.: Application Number:US1996009013 ; Publication Number: Click to see the data
IPC:
A61K 38/36
C12N 15/09
A61K 38/00
A61P 7/02
A61P 9/00
A61P 43/00
C07K 1/107
C07K 1/113
C07K 1/22
C07K 1/36
C07K 14/745
C07K 14/755
C12N 15/12
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
36
Blood coagulation or fibrinolysis factors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
02
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
1
General processes for the preparation of peptides
107
by chemical modification of precursor peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
1
General processes for the preparation of peptides
107
by chemical modification of precursor peptides
113
without change of the primary structure
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
1
General processes for the preparation of peptides
14
Extraction; Separation; Purification
16
by chromatography
22
Affinity chromatography or related techniques based upon selective absorption processes
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
1
General processes for the preparation of peptides
14
Extraction; Separation; Purification
36
by a combination of two or more processes of different types
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
745
Blood coagulation or fibrinolysis factors
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
745
Blood coagulation or fibrinolysis factors
755
Factors VIII
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
12
Genes encoding animal proteins
CPC:
C07K 14/755
A61K 38/00
Applicants: AVENTIS BEHRING L L C
Inventors: FARB DAVID L
HRINDA MICHAEL E
LEE TED C K
PRIOR CHRISTOPHER P
WEBER DAVID
Priority Data: 08487445 07.06.1995 US
9609013 06.06.1996 US
Title: (DE) THERAPEUTISCHE FRAGMENTE DES "VON WILLEBRAND" FAKTORS
(EN) THERAPEUTIC FRAGMENTS OF VON WILLEBRAND FACTOR
(FR) FRAGMENTS THERAPEUTIQUES DU FACTEUR VON WILLEBRAND
Abstract: front page image
(EN) Processes for preparing aqueous solutions of cysteine-altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and containing undesired contaminants, said solution having an acidic pH; separating said contaminants from said solution by contacting said solution with an affinity chromatography medium to which said vWF fragments adhere; eluting said vWF fragment from said affinity chromatography medium in the presence of the denaturant; and separating the eluted fragment from said denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than abouth 5.5 to increase monomerization of, and decrease aggregation of, said fragment, thereby forming an aqueous solution of vWF fragment which is substantially free of aggregate.
(FR) La présente invention concerne des procédés de préparation de solutions de fragments du facteur von Willebrand modifiés par la cystéine, sensiblement exempts d'agrégats et pouvent être employés en thérapeutique pour traiter la thrombose. Le procédé selon l'invention comprend la fourniture d'une solution aqueuse de fragments de FvW et d'un dénaturant contenant des impuretés indésirables, cette solution ayant un pH acide, la séparation des impuretés et de la solution par sa mise en contact avec un produit de chromatographie par affinité auquel les fragments de FvW adhèrent, l'élution desdits fragments de ce produit en présence du dénaturant et la séparation des fragments élués et du dénaturant, le pH de la solution aqueuse de fragments étant maintenu à une valeur d'environ 2,5 à moins d'environ 5,5 pour accroître la monomérisation de ces fragments et réduire leur agrégation, ce qui donne une solution aqueuse de fragments de FvW qui est sensiblement exempte d'agrégats.
Also published as:
MXPA/a/1997/009893JP2001517197 CA2223702KR1019990022634AU1996060471WO/1997/018834